Molecular genetic subtypes of bladder cancer
https://doi.org/10.21886/2308-6424-2023-11-3-108-117
Abstract
Introduction. Bladder cancer (BCa) is one of the most common oncological diseases with many relapses and progressions, which requires more and more new ways to solve this problem.
Objective. To analyse of existing data on the molecular and genetic features of BCa classification based on them, assessment of the possibility of its introduction into clinical practice as a criterion for recurrence and progression.
Materials & methods. We analysed the data of studies on molecular subtypes of BCa published in PubMed, Scientific Electronic Library of Russia (eLibrary), Scopus, Medline, EMBASE, websites of professional associations. We searched the following keywords: "molecular subtypes of bladder cancer", "non-muscle invasive bladder cancer", "molecular subtypes of bladder cancer" "non-muscle invasive bladder cancer". The paper focuses on the current classifications and the April 2020 consensus, which can be universal and applied in everyday practice.
Results. During the analysis of the obtained data, it was revealed that the molecular and genetic heterogeneity of BCa is reflected not only in the proteins expressed on tumor cells, but also in the response to treatment and prognosis of the disease.
Conclusion. Molecular and genetic markers seem promising for introduction into wide clinical practice to adjust treatment and assess the risks of recurrence and progression.
About the Authors
S. V. Kotov
Pirogov Russian National Research Medical University (Pirogov Medical University); Pirogov City Clinical Hospital No.1; «Kommunarka» Moscow Multidisciplinary Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Sergey V. Kotov — M.D., Dr.Sc. (Med), Full Prof.; Head, Dept. of Urology and Andrology; Head, University Clinic of Urology, Oncourology and Andrology; Urologist, Urology Division
Moscow
Competing Interests:
The authors declare no conflicts of interest.
A. L. Khachatryan
Pirogov Russian National Research Medical University (Pirogov Medical University); Pirogov City Clinical Hospital No.1
Russian Federation
Competing Interests:
Russian Federation
Aram L. Khachatryan — M.D., Cand.Sc.(Med); Assist.Prof., Dept. of Urology and Andrology; Urologist, Urology Division
Moscow
Competing Interests:
The authors declare no conflicts of interest.
Sh. M. Sargsyan
Pirogov Russian National Research Medical University (Pirogov Medical University)
Russian Federation
Competing Interests:
Russian Federation
Shagen M. Sargsyan — M.D.; Postgrad. Student, Dept. of Urology and Andrology
Moscow
Competing Interests:
The authors declare no conflicts of interest.
References
1. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam; 2022. ISBN 978-94-92671-16-5
2. Zyatchin I.V., Reva S.A. New treatment options for bladder cancer patients: based on ASCO 2022 materials and beyond. Urology Herald. 2022;10(3):151-155. (In Russian). DOI: 10.21886/2308-6424-2022-10-3-151-155
3. Slovacek H, Zhuo J, Taylor JM. Approaches to Non-Muscle-Invasive Bladder Cancer. Curr Oncol Rep. 2021;23(9):105. DOI: 10.1007/s11912-021-01091-1
4. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130(6):1083-6. DOI: 10.1016/s0022-5347(17)51695-x
5. Kaprin AD, Apolikhin OI, Alekseev BIa, Sivkov AV, Efremov GD, Roshchin DA, Mikhailenko DS, Kachmazov AA, Perepechin DV, Deryagina DM. Clinical, morphological and molecular genetic prognostic factors for survival rates in non-muscle-invasive bladder cancer. P.A. Herzen Journal of Oncology. 2018;7(1):49‑54. (In Russian). DOI: 10.17116/onkolog20187149-54
6. Konyashkina S.Yu., Reva S.A., Petrov S.B. Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer. Urology Herald. 2022;10(4):155-164. (In Russian). DOI: 10.21886/2308-6424-2022-10-4-155-164
7. Бугаев В.Е. Персонализированное лечение рака мочевого пузыря. РООУ. 2020. Ссылка активна на 06.03.2023. Bugaev V.E. Personalized treatment for bladder cancer. RAOU. 2020. (In Russian). Accessed on March 6 2023. https://roou.ru/blog/personalizirovannoe-lechenie-raka-mochevogo-puzyrya
8. Fradet Y, Lafleur L, LaRue H. Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder. J Cell Biochem Suppl. 1992;16I:85-92. DOI: 10.1002/jcb.240501319
9. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008;54(4):835-43. DOI: 10.1016/j.eururo.2007.12.026
10. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187(1):310-4. DOI: 10.1016/j.juro.2011.09.008
11. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433-41. DOI: 10.1016/j.eururo.2010.05.043
12. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012;180(5):1824-34. DOI: 10.1016/j.ajpath.2012.01.023
13. Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumeguere T, Shariat SF, Rorive S, Zlotta AR. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann. 2011;3(3):119-26. DOI: 10.4103/0974-7796.84954
14. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377-86. DOI: 10.1158/1078-0432.CCR-12-0077-T
15. Osetnik V.K., Mamizhev E.M., Dzalilov I.B., Artemyeva A.S., Kushnarev V.A. Molecular subtypes of bladder cancer and first success in personalized treatment. Cancer Urology. 2020;16(1):106-113. (In Russian). DOI: 10.17650/1726-9776-2020-16-1-106-113
16. Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2019;75(3):423-432. DOI: 10.1016/j.eururo.2018.08.027
17. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-433. DOI: 10.1016/j.eururo.2019.09.006
18. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017;72(4):544-554. DOI: 10.1016/j.eururo.2017.03.030
19. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-65. DOI: 10.1016/j.ccr.2014.01.009
20. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016;69(5):855-62. DOI: 10.1016/j.eururo.2015.08.034
21. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, Marandino L, Colecchia M, Lucianò R, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Capitanio U, Montorsi F, de Jong JJ, Dittamore R, Liu Y, Davicioni E, Boormans JL, Briganti A, Black PC, Gibb EA. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(6):701-710. DOI: 10.1016/j.eururo.2020.02.028
22. Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. Clin Cancer Res. 2022;28(23):5107-5114. DOI: 10.1158/1078-0432.CCR-22-2158
Review
For citations:
Kotov S.V., Khachatryan A.L., Sargsyan Sh.M. Molecular genetic subtypes of bladder cancer. Urology Herald. 2023;11(3):108-117. (In Russ.) https://doi.org/10.21886/2308-6424-2023-11-3-108-117
Views:
1102
Email this article 
